当前位置：首页 > 文献互助 > 互助详情

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial复制

用户EO9nReo4Hj6s 1小时前 9 10 已完结

1. 当前求助状态已完结, 请及时下载应助文件

2. 系统将在 2026-07-24 10:35:08 删除文件

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1016/j.jtho.2026.103980复制

文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1556086426004338复制

其他信息:

出版社: Elsevier BV
作者: Ana Baramidze; Tamta Makharadze; Miranda Gogishvili; Tamar Melkadze; Davit Giorgadze; Konstantin Penkov; Konstantin Laktionov; Gia Nemsadze; Marina Nechaeva; Irina Rozhkova; Ewa Kalinka; Yuntong Li; Debra A.G. McIntyre; Xue Jia; Javier Perez; Manika Kaul; Israel Lowy; Jean-Francois Pouliot; Stefanie Chua; Eric Kim; Frank Seebach; Heather Magnan

上一篇：First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer

下一篇：Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis

互助时间线

2026-07-17 10:44:23 [完结求助]

楼主确认了用户YCvDdV4MGyka应助的文件是正确的, 求助状态变成 已完结

2026-07-17 10:35:08 [上传文件]

用户YCvDdV4MGyka上传了文件(pdf 548.49 KB), 求助状态变成 待确认

2026-07-17 10:34:30 [发起求助]

最新发布的求助

Long-term safety and efficacy of intracortical microstimulation in humans 34分钟前
等离子表面改性实现原位生长高分辨率钙钛矿发光二极管 51分钟前
Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial 1小时前
Apatinib combined with capecitabine plus temozolomide versus sunitinib in advanced gastroenteropancreatic neuroendocrine tumours: a propensity score-matched real-world study 1小时前
Biomimetic Shell–Core Nanoparticles Loaded With Apatinib for Dual Starvation and Chemodynamic Combination Therapy of Lung Cancer 1小时前
Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis 1小时前
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-Year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial 1小时前
First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer 1小时前
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial 1小时前
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer 1小时前
Efficacy and Safety of Fibroblast Growth Factor 21 (FGF21) Analogs in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction … 1小时前
Efimosfermin, a Fibroblast Growth Factor 21 Analogue for Metabolic Dysfunction-Associated Steatohepatitis 1小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com